Breast Tumors Metastasis: New Insight into Role of Immune Microenvironment

A special issue of Medical Sciences (ISSN 2076-3271). This special issue belongs to the section "Cancer and Cancer-Related Research".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 2202

Special Issue Editor


E-Mail Website
Guest Editor
Wake Forest School of Medicine, Department of Cancer Biology, 1 Medical Center Blvd, Hanes, Winston Salem, NC 27101, USA
Interests: cancer; dormancy; immune cells; microenvironment; drug resistance; metastasis; lncRNA; mirna; Breast cancer; lung cancer; glioma; gastric cancer

Special Issue Information

Dear Colleagues,

Breast cancer is the most common type of malignancy detected in women, with poor prognosis in higher pathologic grades. Breast tumor metastasis refers to the spread of cancer cells from the primary tumor in the breast to other parts of the body. Metastasis is a complex process and a significant factor in the progression and severity of breast cancer. Distant organs such as the lungs, brain, and bone are observed to be the most frequent metastatic sites. The immune microenvironment plays a significant role in breast cancer metastasis. The immune microenvironment refers to the various immune cells, signaling molecules, and the overall immune response within the tumor and its surrounding tissue. Understanding how the immune system interacts with cancer cells can provide insights into the progression and spread of breast cancer.

This Special Issue will feature original research and review articles focused on, but not be limited to, studies deciphering the role of confounding factors including immune cells in the metastasis of breast cancer to distant organs. The goal is to provide updated information on ongoing research in the complex and dynamic interaction between cancer cells and cells of the immune system and its role in the development of novel therapeutic approaches.    

Dr. Ravindra Deshpande
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • metastasis
  • immune cells
  • lung
  • bone
  • therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 870 KiB  
Article
Survival Analysis of Male Patients with Brain Metastases at Initial Breast Cancer Diagnosis over the Last Decade
by Jorge Avila, Julieta Leone, Carlos T. Vallejo and José P. Leone
Med. Sci. 2024, 12(1), 15; https://doi.org/10.3390/medsci12010015 - 10 Mar 2024
Viewed by 1897
Abstract
Breast cancer in men represents approximately 1% of all breast cancer diagnoses. Among all patients with breast cancer, approximately 30% will develop brain metastases. Over the past decade, there have been multiple advances in the treatment of metastatic breast cancer; however, long-term outcomes [...] Read more.
Breast cancer in men represents approximately 1% of all breast cancer diagnoses. Among all patients with breast cancer, approximately 30% will develop brain metastases. Over the past decade, there have been multiple advances in the treatment of metastatic breast cancer; however, long-term outcomes of this presentation in male patients are lacking. We evaluated male patients with de novo stage IV breast cancer using the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2019. Overall survival (OS) was estimated using the Kaplan–Meier method and differences between groups were compared using log rank tests. In total, 22 male patients with brain metastases at initial breast cancer diagnosis were included. Patients with HR-positive/HER2-negative tumors had the longest OS (median 13 months). Factors associated with shorter overall survival were advanced age, unmarried marital status, lower household income, and grade III disease, among others. Brain metastases remains an unmet medical need for patients with breast cancer; the development of new drugs may provide an improvement in overall survival for male patients in the future. Full article
Show Figures

Figure 1

Back to TopTop